Southeastern Diabetes Initiative Clinical Intervention (SEDI)
A Clinical Intervention to Serve High-Risk Patients in the Southeastern Diabetes Initiative and Durham Diabetes Coalition
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Clinical care will be delivered by a multidisciplinary team including (but not limited to) an physician, nurse practitioner, dietician, pharmacist, licensed clinical social worker (LCSW), case manager, health educator and a community health worker. Care will be delivered in community settings including home visits and community based clinics. With the exception of specific surveys (listed in the Study Intervention section) all data are being collected for the purpose of delivery of standard preventive care and clinical care. The population group will include patients diagnosed with Type 2 Diabetes Mellitus in four Southern United States counties, meeting certain inclusion criteria, and deemed "high risk" as determined by a set of standard criteria or a risk algorithm run on secondary data.
The investigators plan to characterize patients diagnosed or at risk for diabetes mellitus, and allow more detailed knowledge of their health than is provided by standard public health data. The investigators will use descriptive, parametric and non-parametric statistics to describe baseline characteristics (demographics and clinical measures of disease severity) of the sample and will compare responders and dropouts on independent and dependent variables, report any significant differences, and include this in the interpretation of results.
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Mississippi
-
Madison, Mississippi, États-Unis
- Mississippi Public Health Institute
-
-
North Carolina
-
Durham, North Carolina, États-Unis
- Durham County Department of Public Health
-
Kannapolis, North Carolina, États-Unis
- Cabarrus Health Alliance
-
-
West Virginia
-
Williamson, West Virginia, États-Unis
- Williamson Health and Wellness Center
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Adults >=18yrs
- Diagnosis of Type 2 diabetes
- Reside in Durham County, NC, Cabarrus County, NC, Quitman County, MS or Mingo County, WV or the neighboring areas and receive the majority of their healthcare in the four listed counties.
- Have capacity to give consent (or have a surrogate legally authorized representative or caregiver provide consent on their behalf).
- Defined as high risk by the risk algorithm or their primary care clinician.
- Referral from the primary care clinician or patient's medical home if one has been designated.
Exclusion Criteria:
- Lack capacity to make decisions and do not have a surrogate with authority to make health care decisions.
- Have a terminal illness with a life expectancy of 6 months or less
- Diagnosis of Type 1 diabetes or gestational diabetes
- Currently pregnant (confirmed via self-report and/or medical record)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: High Risk group
Extension of Care
|
Clinical care will be delivered by a multidisciplinary team including (but not limited to) a physician, nurse practitioner, dietitian, pharmacist, licensed clinical social worker (LCSW), case manager, health educator and a community health worker in community settings including home visits and community based clinics.
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Mortality
Délai: Up to 24 months
|
Up to 24 months
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Rate of health services utilization
Délai: up to 24 months
|
As measured by inpatient hospital admissions and emergency department visits
|
up to 24 months
|
|
Change in Medication Adherence
Délai: Baseline, 6, 12, 18, and 24 months
|
As measured by the Morisky Medication Adherence Score
|
Baseline, 6, 12, 18, and 24 months
|
|
Change in HbA1c
Délai: Baseline, 6, 12, 18, and 24 months
|
Baseline, 6, 12, 18, and 24 months
|
|
|
Change in blood lipids
Délai: Baseline, 6, 12, 18, and 24 months
|
Measurements include total cholesterol, HDL, LDL, triglycerides
|
Baseline, 6, 12, 18, and 24 months
|
|
Change in blood glucose
Délai: Baseline, 6, 12, 18, and 24 months
|
Baseline, 6, 12, 18, and 24 months
|
|
|
Change in blood pressure
Délai: Baseline, 6, 12, 18, and 24 months
|
Baseline, 6, 12, 18, and 24 months
|
|
|
Incidence of micro- and macro-vascular complications
Délai: Up to 24 months
|
Includes retinopathy, neuropathy, kidney disease, cardiovascular disease
|
Up to 24 months
|
|
Change in patient-reported outcomes
Délai: Baseline, 6, 12, 18, and 24 months
|
Includes results from PHQ 2, PAM-13, PROMIS 9, and REALM-SF surveys
|
Baseline, 6, 12, 18, and 24 months
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chercheur principal: Robert Califf, MD, Duke Translational Medicine Institute
- Chercheur principal: Bryan Batch, MD, Duke University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- Pro00043463
- 1C1CMS331018 (Autre subvention/numéro de financement: Centers for Medicare and Medicaid Services)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .